Connect with us


The Menarini Group invests €150 million for a new plant in Italy

The Menarini Group has decided to stop searching for an attractive international location for the construction of its new plant and to help Italy’s economic recovery. With a name linked to the relaunch of Italy and under the sign of Industry 4.0, the modern factory will produce drugs for millions of people around the world. The investment will amount to $169 million (€150 million).



This picture show a city in italy.

After closing 2019 with a turnover of over $4.17 billion (€3.7 billion), Menarini chose Italy for its new $169 million (€150 million) plant, which will be built in Florence. The plant, which will mark Italy’s desire to start running again after quarantine, will be the most modern and one of the largest in the Group, founded in 1886 in a Neapolitan pharmacy, the Menarini International Pharmacy.

Find out more details about the new plant that the Menarini Group plans to build in Italy and read the most important economic news in the world with our companion app Born2Invest.

The Menarini Group wants to help Italy economically recover from the COVID-19 crisis

The decision to stop the search for the most economically attractive international location, and to favor Italy, has in fact matured during the dramatic days of the lockdown, when the tragic consequences of the pandemic on the Italian economy began to become evident: “We have made a heartfelt decision, shared with the Board of Directors: to favor our country, and to do so immediately, with an investment of $169 million (€150 million) that will immediately contribute to the economy and employment,” commented Lucia and Alberto Giovanni Aleotti, shareholders and members of the Menarini Board. “We are an Italian company and we are proud to be one. Here we will produce drugs that are the essence of the Menarini Group, used every day by tens of millions of patients in Italy and abroad.” 

The site will be built in the Florentine area, occupying 40,000 square metres and will employ 250 people directly and 250 people in the supply chain. It will be a smart manufacturing plant, with innovative production technologies and automation and digitization systems in line with the Industry 4.0 program with important objectives of environmental sustainability. 

The plant will have an annual production capacity of about 100 million packs, corresponding to about 3 billion tablets, and will bring the desire to relaunch the company, thanks to a special initiative: “This plant will have a name, a bit like a child,” continued Lucia and Alberto Giovanni Aleotti. “Our employees will choose it. A name that sums up the courage, the will and the heart of Italy that wants to get up and work as a team in the most difficult moments.”

The company’s growth was driven by international markets

The Menarini Group, which has recently announced the purchase offer for the US biotech company Stemline, closed 2019 with an increase in accounts compared to 2018. Sales were close to $4.28 billion (€3.8 billion) up 3.2% compared to 2018, and Ebitda amounted to $554 million (€492 million). 

The growth was driven by international markets despite the patent expiry of Adenuric (febuxostat), a drug for hyperuricemia. “The year that ended was obviously not affected by the COVID-19 crisis, and saw Menarini increase its presence abroad and strengthen its governance with the appointment, in September, of the Group’s CEO, Elcin Barker Ergun.

“At the moment, international sales account for 77% of the total thanks to the dedication and commitment of our employees, who bring the quality of Menarini’s medicines to the world,” commented Eric Cornut, Chairman of the Menarini Group.


(Featured image by vrolanas via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Andrew Ross is a features writer whose stories are centered on emerging economies and fast-growing companies. His articles often look at trade policies and practices, geopolitics, mining and commodities, as well as the exciting world of technology. He also covers industries that have piqued the interest of the stock market, such as cryptocurrency and cannabis. He is a certified gadget enthusiast.